Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Broadcom Inc (AVGO) vs Twist Bioscience Corp (TWST) Price & Performance

Broadcom IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Broadcom Inc vs Twist Bioscience Corp — how do they compare? Broadcom Inc trades at $393.19 (market cap $1.85T), while Twist Bioscience Corp trades at $92.62 (market cap $5.77B). The key difference: Broadcom Inc is far larger — about 320.6× Twist Bioscience Corp's market cap, and Broadcom Inc pays a 0.67% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

AVGOTWST
Market Cap
$1.85T$5.77B
Sector
TechnologyHealth
52-Week High
$481.57$102.88
52-Week Low
$278.59$24.16
Enterprise Value
$1.90T$5.69B
Dividend Yield
0.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Broadcom Inc

Broadcom (AVGO) trades at $384.05, down 3.98% on the day, but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows bullish technical signals with support at $380 and resistance at $392, while fundamentals reveal impressive profitability with 38.85% net margins and 37.28% ROE. Recent analyst coverage remains overwhelmingly positive with 86% buy ratings.

AVGO presents a compelling growth story with AI-driven revenue expansion and strong cash flow generation, though elevated valuation multiples (P/E 63.9) and high debt levels warrant caution. The consensus price target of $509.70 suggests significant upside potential if execution continues, but investors should monitor competitive pressures in the semiconductor space.

Twist Bioscience Corp

TWST trades at $90.35, down 0.31% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near key support at $89. Revenue growth remains strong, reaching $376.57M in 2025, though the company continues to report net losses. Recent news highlights AI-driven drug discovery collaborations and insider selling activity, while analyst consensus leans bullish with a $91.63 price target.

The stock offers growth exposure to synthetic biology and AI-enabled therapeutics, but carries significant risk due to persistent negative cash flow and profitability challenges. Investor sentiment is cautiously optimistic, balancing innovation potential against financial sustainability concerns in a competitive biotech landscape.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Broadcom Inc

Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.

Read more on AVGO

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST